Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional Cemiplimab vs Surgery in Early Stage CSCC
NCT06585410Phase 3Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2025
- Primary completion
- May 2030
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of cemiplimab in cutaneous squamous cell carcinoma (cSCC) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Event-Free Survival at 1 year. Started Jan 2025; status: recruiting.
02
Drugs
cemiplimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT06585410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06585410.